Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial (vol 29, pg 2825, 2023)

被引：1

作者：

Galsky, Matthew D.

Daneshmand, Siamak

Izadmehr, Sudeh

Gonzalez-Kozlova, Edgar

Chan, Kevin G.

Lewis, Sara

Achkar, Bassam El

Dorff, Tanya B.

Cetnar, Jeremy Paul

Neil, Brock O.

D'Souza, Anishka

Mamtani, Ronac

Kyriakopoulos, Christos

Jun, Tomi

Gogerly-Moragoda, Mahalya

Brody, Rachel

Xie, Hui

Nie, Kai

Kelly, Geoffrey

Horowitz, Amir

Kinoshita, Yayoi

Ellis, Ethan

Nose, Yohei

Ioannou, Giorgio

Cabal, Rafael

Del Valle, Diane M.

Haines, G. Kenneth

Wang, Li

Mouw, Kent W.

Samstein, Robert M.

Mehrazin, Reza

Bhardwaj, Nina

Yu, Menggang

Zhao, Qianqian

Kim-Schulze, Seunghee

Sebra, Robert

Zhu, Jun

Gnjatic, Sacha

Sfakianos, John

Pal, Sumanta K.

机构：

[1] Icahn School of Medicine at Mount Sinai,Division of Hematology and Medical Oncology

[2] Tisch Cancer Institute,Department of Urology

[3] Icahn School of Medicine at Mount Sinai,Department of Oncological Sciences

[4] Keck School of Medicine of USC,Department of Urology

[5] Norris Comprehensive Cancer Center,Department of Radiology

[6] Tisch Cancer Institute,Department of Medical Oncology & Therapeutics

[7] Icahn School of Medicine at Mount Sinai,Division of Hematology and Medical Oncology

[8] City of Hope Comprehensive Cancer Center,Department of Urology

[9] Tisch Cancer Institute,Division of Hematology and Medical Oncology

[10] Icahn School of Medicine at Mount Sinai,Division of Hematology and Medical Oncology

[11] City of Hope Comprehensive Cancer Center,Division of Hematology and Medical Oncology

[12] Oregon Health and Science University,Department of Pathology

[13] University of Utah,Department of Genetics and Genomic Sciences

[14] Keck School of Medicine of USC,Department of Pathology, Molecular and Cell

[15] Norris Comprehensive Cancer Center,based Medicine

[16] University of Pennsylvania Abramson Cancer Center,Department of Radiation Oncology

[17] University of Wisconsin Carbone Cancer Center,Department of Radiation Oncology

[18] Genentech,Department of Urology

[19] Tisch Cancer Institute,Department of Biostatistics and Medical Informatics

[20] Icahn School of Medicine at Mount Sinai,undefined

[21] Human Immune Monitoring Center,undefined

[22] Icahn School of Medicine at Mount Sinai,undefined

[23] Precision Immunology Institute,undefined

[24] Icahn School of Medicine at Mount Sinai,undefined

[25] Icahn School of Medicine at Mount Sinai,undefined

[26] Icahn Institute for Data Science and Genomic Technology,undefined

[27] Icahn School of Medicine at Mount Sinai,undefined

[28] Icahn School of Medicine at Mount Sinai,undefined

[29] Gene Dx,undefined

[30] Dana-Farber Cancer Institute/Brigham & Women’s Hospital,undefined

[31] Harvard Medical School,undefined

[32] Tisch Cancer Institute,undefined

[33] Icahn School of Medicine at Mount Sinai,undefined

[34] Tisch Cancer Institute,undefined

[35] Icahn School of Medicine at Mount Sinai,undefined

[36] University of Wisconsin Carbone Cancer Center,undefined

[37] Formerly with the Icahn School of Medicine at Mount Sinai,undefined

来源：

NATURE MEDICINE | 2024年 / 30卷 / 4期

关键词：

D O I：

10.1038/s41591-024-02814-0

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：1211 / 1211

页数：1

共 50 条

[41] Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial (vol 37, pg 44, 2019)
Coen, John J.
Zhang, Peixin
Saylorv, Philip J.
Lee, Cheryl T.
Wu, Chin-Lee
Parker, William
Lautenschlaeger, Timothy
Zietman, Anthony L.
Efstathiou, Jason A.
Jani, Ashesh B.
Kucuk, Omer
Souhami, Luis
Rodgers, Joseph P.
Sandler, Howard M.
Shipley, William U.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (11) : 1309 - 1309
[42] Combined Chemoradiation Therapy With Twice-Weekly Gemcitabine and Cisplatin for Organ Preservation in Muscle-Invasive Bladder Cancer: Long-Term Results of a Phase 1 Trial
Azria, David
Riou, Olivier
Rebillard, Xavier
Thezenas, Simon
Thuret, Rodolphe
Fenoglietto, Pascal
Pouessel, Damien
Culine, Stephane
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (04): : 853 - 859
[43] A risk score for the prognosis prediction of the muscle-invasive bladder cancer patients who received gemcitabine plus cisplatin chemotherapy
Guo, Yupeng
Dong, Jing
Ji, Tao
Li, Xiaoxia
Rong, Shengzhong
Guan, Hongjun
AGING-US, 2022, 14 (23): : 9715 - 9729
[44] Outcomes of patients following dose-dense neoadjuvant chemotherapy for muscle-invasive bladder cancer: Implications for organ-sparing strategies.
Dumont, Clement
Gauthier, Helene
Mongiat-Artus, Pierre
Masson-Lecomte, Alexandra
Desgrandchamps, Francois
Culine, Stephane
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[45] Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.
Balar, Arjun Vasant
Milowsky, Matthew I.
O'Donnell, Peter H.
Alva, Ajjai Shivaram
Kollmeier, Marisa
Rose, Tracy L.
Pitroda, Sean
Kaffenberger, Samuel D.
Rosenberg, Jonathan E.
Francese, Kaitlyn
Hochman, Tsivia
Goldberg, Judith D.
Griglun, Sarah
Leis, Dayna
Steinberg, Gary D.
Wysock, James
Schiff, Peter B.
Sanfilippo, Nicholas J.
Taneja, Samir
Huang, William C.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[46] Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 study
Han, Sujun
Ji, Zhigang
Jiang, Junhui
Fan, Xinrong
Ma, Qi
Hu, Linjun
Zhang, Wen
Ping, Hao
Wang, Jiansong
Xu, Wanhai
Shi, Benkang
Wang, Wei
Wang, Haifeng
Wang, Honglei
Chen, Shouzhen
Hu, Hailong
Guo, Jianming
Zhang, Shen
Jiang, Shuai
Zhou, Quan
Xing, Nianzeng
CANCER MEDICINE, 2023, 12 (11): : 12106 - 12117
[47] Neoadjuvant nivolumab (N) plus /- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).
Guercio, Brendan John
Pietzak, Eugene J.
Brown, Samantha
Chen, Jie-Fu
Peters, Vanessa
Regazzi, Ashley Marie
Aggen, David Henry
Donahue, Timothy F.
Goh, Alvin C.
Cha, Eugene K.
Donat, S. Machele
Dalbagni, Guido
Bochner, Bernard H.
Funt, Samuel Aaron
Bajorin, Dean F.
Iyer, Gopa
Ostrovnaya, Irina
Al-Ahmadie, Hikmat A.
Rosenberg, Jonathan E.
Teo, Min Yuen
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[48] Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer
de Ruiter, Ben-Max
van Hattum, Jons W.
Lipman, Djoeri
de Reijke, Theo M.
van Moorselaar, R. Jeroen A.
van Gennep, Erik J.
Piet, A. H. Maartje
Donker, Mila
van der Hulle, Tom
Voortman, Jens
Oddens, Jorg R.
Hulshof, Maarten C. C. M.
Bins, Adriaan D.
EUROPEAN UROLOGY, 2022, 82 (05) : 518 - 526
[49] Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712A Randomized Phase II Trial
Coen, John J.
Zhang, Peixin
Saylor, Philip J.
Lee, Cheryl T.
Wu, Chin-Lee
Parker, William
Lautenschlaeger, Timothy
Zietman, Anthony L.
Efstathiou, Jason A.
Jani, Ashesh B.
Kucuk, Omer
Souhami, Luis
Rodgers, Joseph P.
Sandler, Howard M.
Shipley, William U.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (01) : 44 - +
[50] Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC).
Galsky, Matt D.
Harshman, Lauren Christine
Crabb, Simon J.
Wong, Yu-Ning
Yu, Evan Y.
Chowdhury, Simon
Powles, Thomas
Pal, Sumanta Kumar
Moshier, Erin L.
Ladoire, Sylvain
Hussain, Syed A.
Agarwal, Neeraj
Vaishampayan, Ulka N.
Recine, Federica
Berthold, Dominik
Necchi, Andrea
Theodore, Christine
Milowsky, Matthew I.
Bellmunt, Joaquim
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 5 →